Phase lb study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1935-1945

  Saura, Cristina ^a   Bendell, Johanna ^c   Jerusalem, Guy ^e   Su, Shaun ^d   Ru, Qinhua ^d   De Buck, Stefan ^d   Mills, David ^d   Ruquet, Sophie ^g   Bosch, Ana ^h   Urruticoechea, Ander ^b   Beck, Joseph T ⁱ   Di Tomaso, Emmanuelle ^j   Sternberg, David W ^d   Massacesi, Cristian ^g   Hirawat, Samit ^d   Dirix, Luc ^f   Baselga, Jose ^h  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e CHU SART TILMAN   (Belgium)

^f Oncology Centre of Antwerp   (Belgium)

^g Novartis Oncology   (France)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ Highlands Oncology Group   (United States)

^j NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; S6 KINASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANXIETY; ARTICLE; ASTHENIA; BEHAVIOR DISORDER; BREAST CANCER; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERSENSITIVITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES;

EID: 84898730243     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1070     Document Type: Article

References (48)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
3. Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution. Patholog Res Int 2010;2011:903202.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
5. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
6. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. (Pubitemid 46021510)
7. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-44.
8. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91.
9. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55. (Pubitemid 46952930)
10. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44.
11. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and AKT is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-41. (Pubitemid 34791085)
12. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010;126:1121-31.
13. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 2011;16:404- 14.
14. Wee S, Wiederschain D, Maira SM, Loo A, Miller C, DeBeaumont R, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008;105:13057-62.
15. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672-76. (Pubitemid 32667211)
16. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-27. (Pubitemid 39485684)
17. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
18. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502.
19. Chakrabarty A, Bhola NE, Sutton CR, Ghosh R, Kuba MG, Dave B, et al. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 2012;73:1190-200.
20. O'Brien NA, McDonald K, Tong L, Von Euw E, Conklin D, Kalous O, et al. PI3K/mTOR inhibition overcomes in vitro and in vivo trastuzumab resistance independent of feedback activation of pAKT. Cancer Res 2012;72(24 Suppl.):Abstr P4-08-01.
21. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30.
22. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11:317-28.
23. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90.
24. Rodon J, Bendell JC, Razak A, Homji N, Trandafir N, Quadt C, et al. Safety profile and clinical activity of single-agent BKM120, a pan-class I PI3K inhibitor, for the treatment of patients with metastatic breast carcinoma. Cancer Res 2011;71(24 Suppl.):Abstr P3-16-01.
25. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008;27:2420-39. (Pubitemid 351802902)
26. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13. (Pubitemid 32823891)
27. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7. (Pubitemid 43765180)
28. Von Hoff DD, LoRusso P, Demetri GD, Weiss GJ, Shapiro G, Ramanathan RK, et al. A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol 2011;29(15 Suppl.): Abstr 3052.
29. Peyton JD, Rodon Ahnert J, Burris H, Britten C, Chen LC, Tabernero J, et al. A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J Clin Oncol 2011:29(15 Suppl.):Abstr 3066.
30. Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J, et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QDin patients with advanced solid tumors. J Clin Oncol 2011;29(15 Suppl.):Abstr 3020.
31. Edelman G, Bedell C, Shapiro G, Pandya SS, Kwak EL, Scheffold C, et al. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010;28(15 Suppl.):Abstr 3004.
32. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/AKT/ mTOR pathway - beyond rapalogs. Oncotarget 2010;1:530-43.
33. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
34. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
35. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-AKT-mTOR pathway. J Clin Oncol 2012;30:2919-28.
36. Foukas LC, Claret M, Pearce W, Okkenhaug K, Meek S, Peskett E, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006;441:366-70. (Pubitemid 44050203)
37. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96. (Pubitemid 43278292)
38. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006;125:733-47.
39. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19. (Pubitemid 44100518)
40. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, et al. Multiorgan metastasis of human HER-2(+) breast cancer in Rag2 (-/-);Il2rg(-/-) mice and treatment with PI3K inhibitor. PLoS ONE 2012;7:e39626.
41. Maira M, Schnell C, Lollini P, Chouaid C, Schmid P, Nanni P, et al. Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Ann Oncol 2012;23(Suppl. 9): Abstr 1675P.
42. Bandaru SS, Lin K, Roming SL, Vellipuram R, Harney JP. Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav 2010;100:239-44.
43. Tohda C, Nakanishi R, Kadowaki M. Hyperactivity, memory deficit and anxiety-related behaviors in mice lacking the p85alpha subunit of phosphoinositide-3 kinase. Brain Dev 2009;31:69-74.
44. Ackermann TF, Hortnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F, et al. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 2008;22:735-44.
45. Rodon J, Bendell J, Razak ARA, De Jonge MJA, Eskens F, Di Tomaso E, et al. A phase I dose-escalation and expansion trial of BKM120, an oral pan-PI3K inhibitor, in patients with advanced solid tumors: analysis of pharmacodynamic biomarker data. Ann Oncol 2012;23(Suppl. 9):Abstr 457P.
46. Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 2011;29:3126-32.
47. Doi T, Ando Y, Bando H, Yoshino T, Inada M, Mitsuma A, et al. Phase I dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Mol Cancer Ther 2011;10(11 Suppl.):Abstr B159.
48. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Pun-noose EA, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010;16:3670-83.